ClinicalTrials.gg
CompletedNCT05093855Updated Aug 29, 2023

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

A Phase 2 interventional study of BDB-001 Injection in Hidradenitis Suppurativa, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 15 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Hidradenitis Suppurativa with a site in China — 13 open to participants now, 17 under way, 2 of them phase 3. Hidradenitis Suppurativa · China.

Enrollment
14th of 18
41 · median 76
Started
2021
with 1 other
Phase 2
6 of 22
2 open now
Registered
1st of 22
by date
Lead sponsor
2 of 22
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Among the 22 studies in Hidradenitis Suppurativa with a site in China, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 1st registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

13 of the 22 studies in Hidradenitis Suppurativa with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Hidradenitis Suppurativa with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who signed the to participate in the STS-BDB001-06 clinical study and completed all follow-up of the study as required by the protocol, or who withdrew early due to treatment failure or other objective reasons and completed the early withdrawal visit (at least 4 weeks of treatment)

Exclusion criteria

Exclusion Criteria:

  • Never participated in the clinical study of STS-BDB001-06;
  • Subjects withdrew from the STS-BDB001-06 clinical study due to an intolerable adverse event related to the study drug.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Treatment group

    Drug: BDB-001 Injection

Interventions

  • Multiple IV infusions of BDB-001 Injection diluted in sodium chloride

06

What researchers measure

Primary outcomes

  1. Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point

    The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group),IHS4 Score=(Nodule Count) + (Abscess Count\*2) + (Draining Tunnel Count \*4). IHS4 score uses a range grades: Mild=0-3; Moderate=4-10; Severe ≥11.

    Time frame: Week 8

Secondary outcomes

  1. Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point

    The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group),IHS4 Score=(Nodule Count) + (Abscess Count\*2) + (Draining Tunnel Count \*4). IHS4 score uses a range grades: Mild=0-3; Moderate=4-10; Severe ≥11.

    Time frame: From Day 0 until Day 56

  2. Change in modified Sartorius Score (mSS) from Day 0 by time point

    The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.

    Time frame: From Day 0 until Day 56

  3. Change in Hidradenitis Suppurativa Clinical Response (HiSCR) from Day 0 by time point

    The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.

    Time frame: From Day 0 until Day 56

  4. Change in Hidradenitis suppurativa-Physician Global Assessment (HS-PGA) score from Day 0 by time point

    Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA)classifies patients' severity into six categories:clear, minimal, mild, moderate, severe, and very severe, based on the number and quality of inflammatory lesions.

    Time frame: From Day 0 until Day 56

  5. Changes of active lesions (number of inflammatory nodules, abscesses, fistulas, and abscess overflow score) from Day 0 by time point.

    Time frame: From Day 0 until Day 56

  6. Change in Dermatology Life Quality Index (DLQI) score from Day 0 by time point

    A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.

    Time frame: From Day 0 until Day 56

  7. 7. Change in Dermatology visual analog scale (VAS) score from Day 0 by time point.

    Time frame: From Day 0 until Day 56]

  8. Safety of BDB-001 injection in the treatment of patients with HS will be assessed

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: From Day 0 until Day 77

07

Study locations

15 sites
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100144, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100730, China
  • The Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 51063, China
  • Union Hospital Tongji Medical College Huazong University of Science and Technology
    Wuhan, Hubei 100005, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410008, China
  • Chinese Academy of Medical Sciences and Peking Union Medical College
    Nanjing, Jiangsu 210042, China
  • The First Hospital of Jilin Universitv
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110000, China
  • The Second Affiliated Hospital of Air Force Medical University
    Xi'an, Shaanxi 710004, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Huashan Hospital of Fudan University
    Shanghai, Shanghai 200040, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai 200443, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Aug 2023, 24 months.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 24 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Oct 26, 2021
StartActual
Aug 18, 2021
Primary completionActual
Aug 22, 2023
CompletionActual
Aug 22, 2023
Last update
Aug 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05093855
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Aug 18, 2021
Primary completion
Aug 22, 2023
Completion
Aug 22, 2023
Last update
Aug 29, 2023

Study contacts

Baoxi Wang, Master
principal investigator · Plastic Surgery Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion